Curaleaf Pushes Back as Aurora Cannabis Rejects Enhanced Acquisition Bid
Curaleaf Holdings, Inc. (TSX:CURA) has publicly criticized the board of Aurora Cannabis Inc. for rejecting its upgraded takeover proposal and denying it access to financial due diligence. The pushback follows an October 14 notice from Aurora advising its shareholders to turn down Curaleaf's bid, even as Aurora signed confidentiality agreements allowing other unnamed bidders to review non-public financial records.
Curaleaf argues that its revised proposal provides an 86% premium to Aurora's unaffected 30-day average share price, expanding to a 217% premium when excluding cash on the balance sheet. Curaleaf highlighted that Aurora previously issued shares under an equity program for as low as $2.60 per share in July 2026, making its rejection of a $5.00 proposal inconsistent. It also noted that Aurora's adjusted earnings before interest, taxes, depreciation, and amortization fell 63% over its two most recent quarters, raising questions about standalone valuation metrics.
Investors will monitor whether Aurora's board agrees to open due diligence discussions with Curaleaf or if an alternative transaction emerges from competing parties reviewing confidential data. Market reaction was negative for the suitor, with shares of Curaleaf Holdings, Inc. declining 6.90% to 11.07 CAD following the update.
Key points
- Curaleaf Holdings, Inc. challenged Aurora Cannabis Inc. for blocking its due diligence access while permitting other suitors to review confidential financial records.
- Curaleaf stated its enhanced takeover proposal represents an 86% premium over Aurora's unaffected 30-day volume-weighted average share price.
- Aurora previously issued shares at prices as low as $2.60 in July 2026, compared to the $5.00 offer valuation highlighted by Curaleaf.
- Aurora's adjusted EBITDA dropped 63% across its last two quarters, which Curaleaf cited as evidence of ongoing operational headwinds.
- Shares of Curaleaf Holdings, Inc. dropped 6.90% to 11.07 CAD following the corporate update.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why did Curaleaf challenge Aurora Cannabis?
Curaleaf challenged Aurora after its board recommended shareholders reject an upgraded acquisition offer while denying Curaleaf due diligence access that was granted to other potential buyers.
What premium is Curaleaf offering for Aurora Cannabis?
Curaleaf states its offer represents an 86% premium to Aurora's 30-day volume-weighted average price, or 217% on an ex-cash basis, valuing shares at $5.00 each.
How did Curaleaf stock react to the announcement?
Shares of Curaleaf Holdings, Inc. fell 6.90% to 11.07 CAD following the public response.